ERBB2 and esophageal adenocarcinoma: In CheckMate-649, nivolumab plus chemotherapy significantly prolonged OS in HER2-negative gastric, GEJ, and esophageal adenocarcinoma with PD-L1 CPS ≥ 5 (14.4 vs. 11.1 months; HR 0.71), with benefit also seen in the overall population (13.8 vs. 11.6 months; HR 0.80) [56,66,67].